- Home
- SLSR vs EYPT Comparison
SLSR vs EYPT Comparison
Compare SLSR & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLSR
- EYPT
- Stock Information
- Founded
- SLSR 2018
- EYPT 1987
- Country
- SLSR Switzerland
- EYPT United States
- Employees
- SLSR N/A
- EYPT N/A
- Industry
- SLSR
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- SLSR
- EYPT Industrials
- Exchange
- SLSR NYSE
- EYPT Nasdaq
- Market Cap
- SLSR 539.0M
- EYPT 579.4M
- IPO Year
- SLSR N/A
- EYPT 2005
- Fundamental
- Price
- SLSR $5.22
- EYPT $9.93
- Analyst Decision
- SLSR Buy
- EYPT Strong Buy
- Analyst Count
- SLSR 2
- EYPT 8
- Target Price
- SLSR $11.00
- EYPT $24.75
- AVG Volume (30 Days)
- SLSR 62.7K
- EYPT 798.8K
- Earning Date
- SLSR 08-08-2025
- EYPT 08-06-2025
- Dividend Yield
- SLSR N/A
- EYPT N/A
- EPS Growth
- SLSR N/A
- EYPT N/A
- EPS
- SLSR N/A
- EYPT N/A
- Revenue
- SLSR N/A
- EYPT $56,042,000.00
- Revenue This Year
- SLSR N/A
- EYPT N/A
- Revenue Next Year
- SLSR N/A
- EYPT N/A
- P/E Ratio
- SLSR N/A
- EYPT N/A
- Revenue Growth
- SLSR N/A
- EYPT 12.04
- 52 Week Low
- SLSR $1.90
- EYPT $3.91
- 52 Week High
- SLSR $5.88
- EYPT $13.99
- Technical
- Relative Strength Index (RSI)
- SLSR 58.11
- EYPT 59.24
- Support Level
- SLSR $5.16
- EYPT $9.45
- Resistance Level
- SLSR $5.52
- EYPT $11.69
- Average True Range (ATR)
- SLSR 0.28
- EYPT 0.77
- MACD
- SLSR 0.03
- EYPT -0.04
- Stochastic Oscillator
- SLSR 56.61
- EYPT 45.71
About SLSR SOLARIS RESOURCES INC
Solaris Resources Inc is advancing a portfolio of copper and gold assets in the Americas, which includes a high-grade resource with expansion and additional discovery potential at the Warintza copper and gold project in Ecuador; discovery potential on the grass-roots Tamarugo project in Chile and Capricho and Paco Orco projects in Peru, and the La Verde joint venture project.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.